online casino dealer
online casino dealer
None
KMC Solutions hosted its first-ever KMC Hackathon 2024, bringing together over 100 talented developers for two days of intense innovation and collaboration. The event, held last Oct. 24 to 25 at KMC Jollibee Tower in Ortigas, offered an inspiring platform where students and industry professionals competed side by side to tackle real-world recruitment challenges. The grand champion, Craftora from the Technological Institute of the Philippines, made its mark with an incredible story. “I came here with P100, and I’m leaving with P100,000,” Allyza Toquire, one of the Craftora members, remarked, highlighting the life-changing opportunity the Hackathon provided for students. Craftora — comprised of Adriana Cayuba, Carl Jerwin Saguinsin, Ms. Toquire, and Kevin Yu — won for its innovative solution, “Apply Ease,” which streamlined recruitment processes through AI-driven filtering and communication enhancements. Craftora took home P100,000 and a year of Proworking access at KMC Office Spaces. Second place was awarded to Powerhot, with Ariane Lim, Isaiah San Miguel, and Kenneth Alog, who earned P50,000 and six months of Proworking access; while Bravehearts, formed by Cloud Neo Bagtas, Nikka Ysabel Farofaldane, Jann Louis Ontiveros, and Jhonn Raphael, claimed third place, receiving P25,000 and one month of Proworking access. A special recognition for innovation was given to Neosolve, with Vincent Ferrer, Miguel Kalaw, Lauvigne Lumeda, and Kean Rosales, who also received six months of Proworking access at KMC Office Spaces for their creative solution. In collaboration with Brainsparks and UXPH, KMC’s Hackathon focused on the “TalentMatch 2.0: Redesigning the Future of Recruitment” challenge. Teams worked tirelessly to address recruitment inefficiencies, such as improving candidate matching, scheduling, and real-time talent availability tracking. Using AI and mobile-first designs, participants delivered solutions that could revolutionize HR systems. The panel of esteemed judges included industry leaders like Ely Apao, founder of UXPH; Clinton Marsh, CTO of KMC Solutions; Arup Maity, CEO of Xamun.AI; and Chucks Gaza, projects manager of Zoom, among others; as well as industry mentors including Richard Launio of Xamun.AI and Matthew Cua from Brainsparks. More than a competition, KMC’s Hackathon was a testament to the potential of Filipino talent. The event emphasized the possibility for students to compete against established professionals and come out on top, showcasing their creativity, technical skills, and resilience. “We’re not just about building teams; we’re about building communities,” KMC Solutions’ Co-Founder Mike McCullough in his closing remarks for the hackathon. The Hackathon exemplified KMC’s mission to empower Filipino talent, offering students a chance to break barriers and create a lasting impact in the tech industry. Recognized as a Great Place to Work in Asia and a certified B-corp company, KMC fosters an environment where individuals can thrive, supported by a range of upskilling programs and leadership development opportunities.Stocks wavered on Wall Street in afternoon trading Thursday, as gains in tech companies and retailers helped temper losses elsewhere in the market. The S&P 500 was down less than 0.1% after drifting between small gains and losses. The benchmark index is coming off a three-day winning streak. The Dow Jones Industrial Average was up 6 points, or less than 0.1%, as of 1:52 p.m. Eastern time. The Nasdaq composite was down less than 0.1%. Trading volume was lighter than usual as U.S. markets reopened after the Christmas holiday. Chip company Broadcom rose 2.9%, Micron Technology was up 1% and Adobe gained 0.8%. While tech stocks overall were in the green, some heavyweights were a drag on the market. Semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, slipped 0.1%. Meta Platforms fell 0.7%, Amazon was down 0.6%, and Netflix gave up 1.1%. Tesla was among the biggest decliners in the S&P 500, down 1.9%. Health care stocks helped lift the market. CVS Health rose 1.7% and Walgreens Boots Alliance rose 3% for the biggest gain among S&P 500 stocks. Several retailers also gained ground. Target rose 2.8%, Best Buy was up 2.2% and Dollar Tree gained 2.7%. Retailers are hoping for a solid sales this holiday season, and the day after Christmas traditionally ranks among the top 10 biggest shopping days of the year, as consumers go online or rush to stores to cash in gift cards and raid bargain bins. U.S.-listed shares in Honda and Nissan rose 4% and 16%, respectively. The Japanese automakers announced earlier this week that the two companies are in talks to combine. Traders got a labor market update. U.S. applications for unemployment benefits held steady last week , though continuing claims rose to the highest level in three years, the Labor Department reported. Treasury yields turned mostly lower in the bond market. The yield on the 10-year Treasury fell to 4.57% from 4.59% late Tuesday. Major European markets were closed, as well as Hong Kong, Australia, New Zealand and Indonesia. Trading was expected to be subdued this week with a thin slate of economic data on the calendar. Still, U.S. markets have historically gotten a boost at year’s end despite lower trading volumes. The last five trading days of each year, plus the first two in the new year, have brought an average gain of 1.3% since 1950. So far this month, the U.S. stock market has lost some of its gains since President-elect Donald Trump’s win on Election Day, which raised hopes for faster economic growth and more lax regulations that would boost corporate profits. Worries have risen that Trump’s preference for tariffs and other policies could lead to higher inflation , a bigger U.S. government debt and difficulties for global trade. Even so, the U.S. market remains on pace to deliver strong returns for 2024. The benchmark S&P 500 is up roughly 26% so far this year and remains near its most recent all-time high it set earlier this month — its latest of 57 record highs this year. Wall Street has several economic reports to look forward to next week, including updates on pending home sales and home prices, a report on U.S. construction spending and snapshots of manufacturing activity. AP Business Writers Elaine Kurtenbach and Matt Ott contributed.
Biden calls for Assad to be 'held accountable'Donald Trump promises ‘unity’ in preview of inaugural address
BUDAPEST - World Athletics president Sebastian Coe said on Nov 22 the new Ultimate Championship team event, officially unveiled by the sport’s governing body, would be a “gamechanger” for track and field. The inaugural event will be held in Budapest on Sept 11-13, 2026, and it will be staged every two years to fulfil World Athletics’ ambition of holding a global championship every year. The federation said the event would provide “a spectacular conclusion to the summer athletics season, in the years where there is no World Athletics Championships”. The event boasts a “record-setting” prize pot of US$10 million (S$13 million). World Athletics said it was “the largest ever offered in track and field”, with champions set to receive US$150,000. Each session will last three hours and athletes will represent both themselves and their national teams, wearing national kit. Coe, who gave a press conference at the stadium in the Hungarian capital where the 2023 World Championships were held, said: “This new global event will be a gamechanger for our sport and for our athletes. “We want to bring our fans athletics like they have never seen it before – with the best of the best athletes in our sport competing head-to-head in a passion-fuelled, high octane, festival of sport, with sound, light and innovation.” Coe said he was aiming to create a “world-beating” event that could “draw in viewers who might never have watched athletics”. “This is the holy grail of all sports - how do you reach out to all audiences in a way that is familiar to them?“ he told AFP in an interview. The announcement comes after former Olympic sprint champion Michael Johnson unveiled details of his four-meet Grand Slam Track series, which makes its debut next year with three-day events in Kingston, Jamaica, Miami, Philadelphia and Los Angeles. Johnson’s series is widely seen as a challenge to the established Diamond League circuit of meets as the sport of athletics fights for the limelight outside of the Olympics and world championships. The Ultimate Championship, which unlike Grand Slam Track will also feature field events, will take place after the Diamond League finals. In another difference between Grand Slam Track and the Ultimate Championship, World Athletics already have a broadcast partner for their event - Tata Communications and Host Broadcast Services (HBS). Coe said the aim was to have a “free-to-air” event that would be seen by the biggest audience possible, adding: “It’s all up there for discussion.” Grand Slam Track, meanwhile, is yet to announce a broadcasting deal, with Johnson insisting he is still trying to find the right partner. In the Ultimate Championship in Budapest, almost 400 athletes will battle to become “ultimate champions”, with clashes including the 100m, 800m, pole vault, high jump and a new 4x100m mixed relay. World Athletics chief executive officer Jon Ridgeon said the new event coupled with the launch of Grand Slam Track showed that “athletics is in a positive growth phase at the moment”. World pole vault record holder and two-time Olympic champion Mondo Duplantis said the event would be “insane”. “The new Ultimate Championship in 2026 will be the ultimate high in a year when we do not have a World Championships or Olympic Games,” the Swede said. “Nothing beats competing in front of a live crowd. Anyone that knows me or has watched me compete knows this is where I thrive. “Even with fewer events there will still be 26 individual events taking place over just three nights - the pace will be insane.” AFPPakistan takes pride in friendship with Saudi Arabia: Naqvi
Stock market today: Wall Street slips to a rare back-to-back lossPresident-elect Donald Trump joined the chorus of people raising concerns about mysterious drone sightings over New Jersey and other states on the East Coast, calling on government officials to shoot down the aircraft if they are truly unidentifiable. In a Friday post on his social media platform Truth Social , Trump indicated that he believes authorities know more about the drones than they are letting on. “Mystery Drone sightings all over the Country. Can this really be happening without our government’s knowledge. I don [sic] think so! Let the public know, and now. Otherwise, shot [sic] them down!!! DJT,” the president-elect wrote. Residents of Morris County, New Jersey, first started reporting nighttime sightings of the drones last month. Since then, the FBI and the Department of Homeland Security have investigated the objects and are looking into whether people are seeing actual drones, manned aircraft or something else. “We have no evidence at this time that the reported drone sightings pose a national security or public safety threat or have a foreign nexus,” the FBI and DHS said in a joint statement Thursday. “Upon review of available imagery, it appears that many of the reported sightings are actually manned aircraft, operating lawfully. There are no reported or confirmed drone sightings in any restricted air space.” Nevertheless, reports of drone sightings continued to proliferate on Friday, with even former Maryland Gov. Larry Hogan posting video of what he said were “dozens of large drones” flying over his home on Thursday night. Individuals in New York and Connecticut have also reported seeing the aircraft. Trump’s missive came after White House national security spokesperson John Kirby appeared on Fox News ’ “The Story” on Friday afternoon, where host Martha MacCallum pressed him about whether officials really do not have an explanation for the drone sightings. “I’m not going to lie to you or to the American people, and I’m not going to say we know something when we don’t,” Kirby said. “And we would never, ever stoop to think that an American citizen was crazy or nuts because of what they’re seeing and what they’re documenting. We’re taking that imagery seriously and we’re doing the best we can to analyze it, and we encourage people to come forward if they have additional sightings.” “Why not just take one down and figure out what’s going on?” MacCallum asked. “We don’t have enough conclusions to take that kind of a policy action,” Kirby replied. “But let’s just assume for a minute, Martha, that we did. You’re not going to want to shoot something down where it could hit somebody’s house, or hurt somebody.” Don't let this be the end of the free press. The free press is under attack — and America's future hangs in the balance. As other newsrooms bow to political pressure, HuffPost is not backing down. Would you help us keep our news free for all? We can't do it without you. Can't afford to contribute? Support HuffPost by creating a free account and log in while you read. You've supported HuffPost before, and we'll be honest — we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you. Whether you give once or many more times, we appreciate your contribution to keeping our journalism free for all. You've supported HuffPost before, and we'll be honest — we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you. Whether you give just one more time or sign up again to contribute regularly, we appreciate you playing a part in keeping our journalism free for all. Already contributed? Log in to hide these messages. She also asked what President Joe Biden has to say on the issue, and whether Elon Musk or other “outside experts” had been called in to give their opinions. Biden “has tasked the team to look into this and to be energetic in doing it, to try to get answers,” Kirby said. Related From Our Partner
SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.When dockworkers walked the picket line in October, the strike lasted for 3 days. And if a new contract between their 45,000 member union and the U.S. Maritime Alliance isn't signed by mid-January — a longer strike could send inflation going in the wrong direction. Just months after a strike at Gulf and East Coast ports ended, operators and union members are now at an impasse — once again — over automation. Port operators say they need more technology to increase port efficiency, improve safety and to control costs. But union members say no, because some workers will lose their jobs. A new strike could come if an agreement isn't reached by January 15. And if that happens inflation could increase, when goods aren't flowing in an out of ports as quickly. Thursday union leaders met with President-elect Donald trump at Mar-a-Lago and walked away with his support. Writing about automation on Truth social, Trump said "the amount of money saved is nowhere near the distress, hurt, and harm it causes for American workers," and that foreign countries "...shouldn't be looking for every last penny knowing how many families are hurt." RELATED STORY | Billions of dollars of U.S. economic activity halted as port workers enter day two of their strike Professor Todd Belt of George Washington University called it Trump striking a different path than he did during his first term. "During the first Trump term you had Donald Trump, surrounded by a lot of people who were suggested to him by incumbent Republicans who had really a Republican orthodoxy on free trade. Donald trump now is going to be surrounded by a lot of people who support his ideas of interventionism and tariffs, as well as other trade policies that will protect working people at the expense of, of course, inflation," Belt said. The International Longshoremen's Association has until Jan. 15 to negotiate a new contract with the U.S. Maritime Alliance, which represents ports and shipping companies. At the heart of the dispute is whether ports can install automated gates, cranes and container-moving trucks that could make it faster to unload and load ships. The union argues that automation would lead to fewer jobs, even though higher levels of productivity could do more to boost the salaries of remaining workers. The Maritime Alliance said in a statement that the contract goes beyond ports to "supporting American consumers and giving American businesses access to the global marketplace — from farmers, to manufacturers, to small businesses, and innovative start-ups looking for new markets to sell their products." "To achieve this, we need modern technology that is proven to improve worker safety, boost port efficiency, increase port capacity, and strengthen our supply chains," said the alliance, adding that it looks forward to working with Trump. In October, the union representing 45,000 dockworkers went on strike for three days, raising the risk that a prolonged shutdown could push up inflation by making it difficult to unload container ships and export American products overseas. The issue pits an incoming president who won November's election on the promise of bringing down prices against commitments to support blue-collar workers along with the kinds of advanced technology that drew him support from Silicon Valley elite such as billionaire Elon Musk. Trump sought to portray the dispute as being between U.S. workers and foreign companies, but advanced ports are also key for staying globally competitive. China is opening a $1.3 billion port in Peru that could accommodate ships too large for the Panama Canal. There is a risk that shippers could move to other ports, which could also lead to job losses. Mexico is constructing a port that is highly automated, while Dubai, Singapore and Rotterdam already have more advanced ports. "For the great privilege of accessing our markets, these foreign companies should hire our incredible American Workers, instead of laying them off, and sending those profits back to foreign countries," Trump posted. "It is time to put AMERICA FIRST!" The Associated Press contributed to this report.
